Enanta Pharmaceuticals (ENTA) PT Raised to $67 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ENTA Hot Sheet
Price: $10.82 +4.34%
Rating Summary:
15 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
15 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams raised the price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $67.00 (from $64.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
- Procore Technologies, Inc (PCOR) PT Raised to $85 at Stifel
- RxSight Inc. (RXST) PT Lowered to $5 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
